B7-H3 in glioblastoma and beyond : significance and therapeutic strategies

Babič, Davor (avtor), Jovchevska, Ivana (avtor), Zottel, Alja (avtor)

Cancer has emerged as the second most prevalent disease and the leading cause of death, claiming the lives of 10 million individuals each year. The predominant varieties of cancer encompass breast, lung, colon, rectal, and prostate cancers. Among the more aggressive malignancies is glioblastoma, categorized as WHO stage 4 brain cancer. Following diagnosis, the typical life expectancy ranges from 12 to 15 months, as current established treatments like surgical intervention, radiotherapy, and chemotherapy using temozolomide exhibit limited effectiveness. Beyond conventional approaches, the exploration of immunotherapy for glioblastoma treatment is underway. A methodology involves CAR-T cells, monoclonal antibodies, ADCC and nanobodies sourced from camelids. Immunotherapy’s recent focal point is the cellular ligand B7-H3, notably abundant in tumor cells while either scarce or absent in normal ones. Its expression elevates with cancer progression and serves as a promising prognostic marker. In this article, we delve into the essence of B7-H3, elucidating its function and involvement in signaling pathways. We delineate the receptors it binds to and its significance in glioblastoma and other cancer types. Lastly, we examine its role in immunotherapy and the utilization of nanobodies in this domain.

• Jezik: Angleški jezik
• Ključne besede: glioblastoma, B7-H3, CD276, signaling pathways, immune checkpoints, immunotherapy
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2024
• Št. strani: 21 str.
• Številčenje: Vol. 15, art. 1495283
• PID: 20.500.12556/RUL-165583
• UDK: 616-097
• ISSN pri članku: 1664-3224
• DOI: 10.3389/fimmu.2024.1495283
• COBISS.SI-ID: 216635139
• Datum objave v RUL: 09.12.2024

Gradivo je del revije

• Naslov: Frontiers in immunology
• Skrajšan naslov: Front. immunol.
• Založnik: Frontiers Research Foundation
• ISSN: 1664-3224
• COBISS.SI-ID: 30774233

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: glioblastom, signalne poti, imunske kontrolne točke, imunoterapija

Projekti

• Financer: ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
• Številka projekta: P1-0390
• Naslov: Funkcijska genomika in biotehnologija za zdravje

• Financer: ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
• Številka projekta: Z3-4510
• Naslov: Vpliv imunoterapije z anti-PD-L1 atezolizumabom in nanotelesom Nb202 na organoide glioblastoma, pripravljene iz tkiva bolnikov